TCL Archive Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa. January 7, 2005
TCL Archive NCAB ‘Incredulous’ Over Proposed Ethics Rules, Bard Members Threaten Resignation In Letter October 4, 1991
TCL Archive Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial October 31, 2014
TCL Archive In Brief: Calabresi Named DCT Board Chairman; NCI Gets $5 Million Gifts for Intramural Breast Cancer Work June 20, 1986
TCL Archive Accelerated Approval Will No Longer Block Competitors, FDA Commissioner Says June 6, 2003
